Phase 2
Completed N=202
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
Source: ClinicalTrials.gov NCT01395017 ↗Enrolled (actual)
202
Serious AEs
50.7%
Results posted
Mar 2015
Primary outcomePrimary: Overall Survival — 375; 393 Days — p=0.3864
Summary
The purpose of this study is to determine whether patients with locally advanced pancreatic cancer who receive dasatinib added to standard of care (gemcitabine) live longer, compared to patients who receive standard of care (gemcitabine) plus placebo; i.e. gemcitabine alone.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Survival |
375; 393 | 0.3864 |
| SECONDARY Progression Free Survival (PFS) |
167; 166 | 0.6761 |
Eligibility Criteria
Inclusion Criteria
- Histologic or cytologic documentation of unresectable adenocarcinoma of the pancreas.
- Recovery from toxicity of previous procedures to establish the diagnosis. ECOG PS 0 or 1.
- Adequate organ function.
Exclusion Criteria
- Evidence of metastatic disease.
- Previous radiotherapy or chemoradiotherapy.
- History of or current pleural effusion.
- History of significant cardiovascular disease.
- Clinically significant bleeding disorder or coagulopathy.
- Concomitant medication with strong CYP 3A4 inhibitor.
Data sourced from ClinicalTrials.gov (NCT01395017). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.